Problems in the Treatment of Parkinsonism

  • Roger C. Duvoisin

Abstract

The progress achieved in our understanding of parkinsonism and its treatment in the last decade has greatly improved the lot of our patients but has also brought new sets of problems. The very effectiveness of levodopa therapy has modified the clinical spectrum of symptomatology. By suppressing tremor and rigidity and prolong ing our patients’ lives, we have uncovered other manifestations of parkinsonism which were previously less prominent. The greater specificity of levodopa has rendered precise diagnosis more important, but at the same time the recognition of new entities has changed the nosology of parkinsonism. Although the diagnosis of extrapyramidal disorders depends almost exclusively on clinical observation, new diagnostic tools are beginning to alter the character of neurology and promise to have a significant impact on the clinical evaluation of patients with basal ganglia diseases.

Our better understanding of the modus operands of various drugs used in treating extrapyramidal disorders has in some ways complicated the physician’s task. In place of the simple empiricism that prevailed a decade ago, there is now a body of knowledge and theory which one must appreciate to obtain optimal therapeutic results.

The remarkable relief of Parkinsonian symptomatology possible in some patients has thrown into relief cases of treatment failure and placed additional emphasis on manifestations of parkinsonism which are either unresponsive to therapy or are actually exacer-bated by it. Finally, the diagnosis and management of intercurrent illnesses in Parkinson patients on levodopa therapy has presented additional new problems to the clinician.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Caplan, L.H., Jacobson, H.G., Rubinstein, B.M. and Rotman, M.Z. (1965). Megacolon and volvulus in Parkinson’s disease. Radiology 85: 73–79.PubMedGoogle Scholar
  2. Charcot, J.M. (1886) Leoons sur les maladies du Systeme nerveux. Paris, Delahaye et Lecrosnier.Google Scholar
  3. Cotzias, C., Van Woert, M. and Schieffer, L. (1976) New Eng. J. Med. 276: 374–379.CrossRefGoogle Scholar
  4. Critchley, M. (1929). Arterioschlerotic Parkinsonism. Brain 52: 23–83.Google Scholar
  5. Denny-Brown, D. (1962). The Basal Ganglia. Oxford Univ. Press, London, pp. 72–73 and Fig. 30.Google Scholar
  6. Duvoisin, R.C. (1972). Diphenidol for levodopa induced nausea and vomiting. J. A. M. A. 221: 1408.PubMedCrossRefGoogle Scholar
  7. Duvoisin, R.C. Yahr, M.D. and Cote, L.J. (1969). Pyridoxine reversal of L-dopa effects in Parkinsonism. Trans. Am. Neurol. Assoc. 94: 81–84.PubMedGoogle Scholar
  8. Duvoisin, R.C. and Yahr, M.D. (1972). In: L-Dopa and Behavior Ed. by S. Malitz, New York, Raven Press, pp. 57–72.Google Scholar
  9. Duvoisin, R.C., Yahr, M.D., Lieberman, J., Antunes, J., and Rhee, S. (1972). The striatal foot. Trans. Am. Med. Assoo. 97: 267.Google Scholar
  10. Duvoisin, R.C. (1975). Antagonism of levodopa by papaverine. J. A. M. A. 231 (8): 845–846.PubMedCrossRefGoogle Scholar
  11. Duvoisin, R.C. (1975). Alpha-methyldopa and Parkinsonism: Induction or Exacerbation. Neurology 25: 376.Google Scholar
  12. Duvoisin, R.C. and Marsden, CD. (1975). Note on the scoliosis of Parkinsonism. J. Neurol. Neurosurg, &Psychiat. 38: 787–793.CrossRefGoogle Scholar
  13. Forno, L.S. and Alvorol, E.C (1971). In: Recent Advances in Park inson’s Disease. Ed. by F.H. McDowell and CH. Markham. pp. 119–162.Google Scholar
  14. Gilbert, G.J. (1967). Lancet ii: 442–443.Google Scholar
  15. Henry, R.E., Goldberg, L.J., Sturgen, P. and Ansel, R.D. (1971). Serologic abnormalities associated with L-dopa therapy. Vox Sang. 20: 306–316.PubMedCrossRefGoogle Scholar
  16. Joseph, C (1972). Occurrence of positive coombs test in patients treated with levodopa. New Eng. J. Med. 286: 1401–1402.PubMedCrossRefGoogle Scholar
  17. Ratput, H., Kazi, K.G. and Rozdilski, B. (1972). Striatonigral degeneration response to levodopa therapy. J. Neurol. Sci. 16: 331–341.CrossRefGoogle Scholar
  18. Selby, G. (1968). Cerebral atrophy in Parkinsonism. J. Neurol. Sci. 6: 517–559.PubMedCrossRefGoogle Scholar
  19. Skibba, J.L., Pinckney, J., Gilbert, E.F. and Johnson, R.W. (1972). Multiple primary melanoma following administration of levodopa. A&ch. Pathol. 93: 556–561.Google Scholar
  20. Stadlan, E.M., Duvoisin, R.C. and Yahr, M.D. (1966) in Proceedings of the Vth International Congress of Neuropathology. Ed. by F. Luthy and A. Bischoff. Amsterdam, Excerpta Medica. pp. 569–571.Google Scholar
  21. Takei, Y. and Mirra, S.S. (1973) in Progress in Neuropathology ,Vol. II Ed. by A.M. Zimmerman, New York, Grune and Stratton, pp. 217–251.Google Scholar
  22. Territo, M.C., Peters, R.W. and TAnaka, K.R., (1973) J. A. M. A. 226: 347–348.CrossRefGoogle Scholar
  23. Wolf, S.M. and Davis, R.L., (1973). Permanent dementia in idiopathic Parkinsonism treated with levodopa. Arch. Neurol. 29: 276–278.PubMedCrossRefGoogle Scholar
  24. Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E. and Hoehn, M.M. (1969). Treatment of Parkinsonism with levodopa. Arch. Neurol. (Chicago) 2: 343–345.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Roger C. Duvoisin
    • 1
  1. 1.Department of Neurology, The Mount Sinai School of MedicineThe City University of New YorkNew YorkUSA

Personalised recommendations